Inhibitor | Compound or drug | Targets | Tumor types currently under investigation |
---|---|---|---|
PI3K | LY294002 | Pan-class I PI3K | Advanced solid tumors |
Buparlisib (BKM120) | Pan-class I PI3K | Advanced solid tumors | |
SAR245408 (XL-147) | Pan-class I PI3K | Advanced solid tumors | |
Sonolisib (PX-866) | P110-Delta, gamma | Phase II and III trials in NHL and CLL are underway, both alone and in combination with hantiCD20 antibodies | |
Pictilisib (GDC-0941) | P110-alpha, Delta | Added alpha specificity may provide benefit in MCLandsome others versus delta-only inhibitors | |
Taselisib (GDC-0032) | P110-alpha, Delta | Advanced solid tumors and metastatic breast cancer (ERþ) | |
AKT | Pirifosine | AKT | Advanced solid tumors, multiple myeloma |
Palomid529(P529) | AKT | Advanced solid tumors, breast cancer, cervical cancer, endometrial cancer, leukemias, melanoma, multiple myeloma | |
GSK2141795 | AKT | Advanced solid tumors, breast cancer, cervical cancer, endometrial cancer, leukemias, melanoma, multiple myeloma | |
MK-2206 | AKT | Advanced solid tumors, breast cancer, colorectal cancer, endometrial cancer, head & neck cancer, lung cancer, lymphomas, pancreatic cancer, prostate cancer | |
mTOR | Everolimus(RAD001) | mTORC1 | Approved for the treatment of renal cell carcinoma, subependymal giant cell astrocytoma associated with tuberous sclerosis, pancreatic neuroendocrine tumors, and ERþ breast cancer |
Temsirolimus | mTORC1 | Approved for the treatment of renal cell carcinoma | |
Rapamycin | mTORC1 | Advanced solid tumors, multiple myeloma | |
Dual | NVP-BEZ235 (BEZ-235) | P110, mTORC1/2 | Advanced solid tumors, multiple myeloma |
SAR245409(XL765) | PI3K/mTOR | Advanced solid tumors, CLL, indolent non-Hodgkin lymphoma, mantle cell lymphoma, ovarian cancer | |
GDC-0980 | PI3K/mTOR | Solid cancers, non-Hodgkin lymphoma, breast cancer, prostate cancer |